Search results
Results from the WOW.Com Content Network
Dipeptidyl peptidase 4 (DPP-4) inhibitors are a class of medicine that lower high blood glucose levels and may be used in the treatment of type 2 diabetes. DPP-4 inhibitors slow the inactivation and degradation of GLP-1, a hormone involved in glucose removal from the gut.
This topic will review the mechanism of action and therapeutic utility of DPP-4 inhibitors for the treatment of type 2 diabetes mellitus. GLP-1 receptor agonists are discussed separately.
Inhibitors of dipeptidyl peptidase 4 (DPP-4 inhibitors or gliptins) are a class of oral hypoglycemics that block the enzyme dipeptidyl peptidase-4 (DPP-4). They can be used to treat diabetes mellitus type 2. The first agent of the class – sitagliptin – was approved by the FDA in 2006. [1]
DPP-4 inhibitors, known as gliptins, are a class of oral diabetic medications approved by the Food and Drug Administration (FDA) to treat type 2 diabetes mellitus in adults. DPP-4 inhibitors that have FDA approval include sitagliptin, saxagliptin, linagliptin, and alogliptin.
DPP-IV inhibitors are recommended for patients with type 2 diabetes who have poorly controlled blood glucose and high Hb A1c levels. On average, most patients find that their A1c levels drop by 0.5-1.0% on these medications.
This topic will review the mechanism of action and therapeutic utility of DPP-4 inhibitors for the treatment of type 2 diabetes mellitus. GLP-1 receptor agonists are discussed separately.
DPP-IV inhibitors are FDA approved for use as monotherapy in type 2 diabetes (T2DM). DPP-IV inhibitors can also be added to patients already on metformin, sulfonylureas, thiazolidinediones, or insulin. If adding DPP-IV inhibitors to sulfonylurea /insulin therapy, consider decreasing the sulfonylurea/insulin dose, to reduce hypoglycemia risk.
DPP-4 inhibitors are a class of prescription medicines that are used with diet and exercise to control high blood sugar in adults with type 2 diabetes. Medicines in the DPP-4 inhibitor class...
This Review discusses the use of the five main dipeptidyl peptidase 4 inhibitors for this purpose, highlighting their benefits and risks.
Objective To assess the efficacy and safety of dipeptidyl peptidase-4 (DPP-4) inhibitors compared with metformin as monotherapy, or with other commonly used hypoglycaemic drugs combined with metformin, in adults with type 2 diabetes mellitus.